Clinical trial
Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
NCT06263881 is registered in ClinicalTrials.gov with Materia Medica Holding as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
- Lead sponsor
- Materia Medica Holding
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 1, 2023
- Completion date
- March 19, 2025
- Enrollment
- 370 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.